USFDA conducts product specific pre-approval inspection at Lupin Ltd's Aurangabad facility

The U.S. FDA has conducted a product-specific Pre-Approval Inspection (PAI) at Lupin Ltd's Chhatrapati Sambhajinagar (Aurangabad) manufacturing facility from September 01 to September 05, 2025. The inspection closed with two observations.

We will address the observations and respond to the U.S. FDA within the stipulated timeframe. We are committed to be compliant with CGMP quality standards across all our facilities.

Shares of Lupin Limited was last trading in BSE at Rs. 1944.65 as compared to the previous close of Rs. 1939.40. The total number of shares traded during the day was 25255 in over 1606 trades.

The stock hit an intraday high of Rs. 1970.00 and intraday low of 1932.70. The net turnover during the day was Rs. 49206815.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA PreApprovalInspection Aurangabad ManufacturingFacility